Objectives:
Introduction
Type-A, phospholipases (PLA,) are ubiquitously distributed in eukaryotic cells. They catalyze the cleavage of fatty acids from the m-2 position of phospholipids. During myocardial ischemia a significant degradation in phospholipids and an accumulation of lysophospholipids has been reported [ 1 ,z] . Enhanced extracellular calcium-dependent PLA, activity was thought to be responsible for the accumulation of these potentially toxic metabolites. However, no increase in calcium-dependent PLA, activity during ischemia has been documented. Furthermore, compounds which inhibit the calcium-dependent PLA, have no consistent cardioprotective efficacy [3, 4] .
Several different subtypes of PLA, which differ in their location [3,1 I] , requirement for calcium [3, 5] , substrate specificity [6, 7] and ATP sensitivity [8, 9] have been identified. The classically studied calcium-dependent PLA, has been shown to represent only 20% of the total myocardial PLA, activity. The remaining 80% is represented by a calcium-independent PLA 2 [7] .
This PLA, has substrate specificity for plasmalogens [7] , a basic pH optimum, and a requirement for ATP [8, 9] .
Since its initial identification in canine myocardium it has also been isolated from human and rabbit myocardium [8, 10] as well as pancreatic p cells and smooth muscle cells [ 11, 121 . An isoform of phosphofructokinase is specifically and tightly associated with this PLA, 1131. The tetramer of this isoform makes up the regulatory unit of the PLA r, presumably coordinating regulation of phospholipolysis and glycolysis. Furthermore, the activity of this enzyme increases in rabbit hearts subjected to global ischemia and may thus be responsible for the phospholipolysis observed during ischemia [ 14, 15] .
Two structurally different classes of compounds have been reported to inhibit a similar PLA,; bromoenol lactone derivatives [16] and benzenesulfonamide derivatives [17] . The first goal of this study was to determine if a bromoenol lactone PLA, inhibitor can protect ischemic/reperfused rat hearts. There are also reports suggesting arachidonic acid, a major product of PLA, activity, directly modulates myocardial K,, [18] . In a recent publication, also suggest a link between the intracellular calcium-independent PLA, and K *rP in insulinoma cells. The second aim was to determine if the cardioprotective effect of the bromoenol lactone PLA, inhibitor is due to activation of K,,,. This was done by studying the effects of K,,, blockers on the cardiac actions of the bromoenol lactone.
Methods

Materials
The bromoenol lactone (see structure in Fig. 1 ) and sodium 5hydroxydecanoate (5-HD) were synthesized by the Medicinal Chemistry Department, Bristol-Myers Squibb as described previously [16, 17] . Plasmalogen and lysoplasmalogen obtained from bovine heart were purchased from Avanti Polar Lipids (Alabaster, AL). Radiolabeled plasmalogen was prepared by acylating lysoplasmalogen with 3H-arachidonic acid to a specific activity of 9300 mCi/mmol using the protocol of Han et al [20] . All other chemicals and materials were obtained from Sigma Chemical Company (St. Louis, MO, USA).
2.2. Preparation and protocols for isolated rat heart experiments 2.2.1. Preparation of isolated rat hearts Male Sprague-Dawley rats (450-550 g) were anesthetized using 100 mg/kg sodium pentobarbital (i.p.1. This investigation conforms with the guide for the care and use of laboratory animals published by the US National Institutes for Health. The trachea was intubated and the jugular vein was injected with heparin (1000 U/kg). While the rats were mechanically ventilated, their hearts were perfused in situ via retrograde cannulation of the aorta. The hearts were then excised and quickly moved to a Langendorff apparatus where they were perfused with oxygenated Krebs-Henseleit solution containing (in n&I): 112 NaCI, 5 KCl, 1.2 MgSO,, 1 KH,PO,, 1.25 CaCl,, 11.5 glucose and 2 pyruvate at a constant perfusion pressure (85 mmHg). A water-filled latex balloon attached to a metal cammla was inserted into the left ventricle and connected to a Statham pressure transducer for measurement of left ventricular pressure. The hearts were allowed to equilibrate for 15 min, at which time end diastolic pressure (EDP) was adjusted to 5 mmHg and this balloon volume was maintained for the duration of the experiment. Pre-ischemia or pre-drug function, heart rate and coronary flow (extracorporeal electromagnetic flow probe, Carolina Medical Electronics, King, NC) were then measured. Left ventricular developed pressure (LVDP) was calculated from the difference between EDP and left ventricular peak systolic pressure. Heart rate was determined from the pressure recordings (systolic peaks). The flow probe was placed upstream (on the tubing exiting the perfusate reservoir) and in-line to the heart. Cardiac temperature was maintained throughout the experiment by submerging the hearts in 37°C buffer which was allowed to accumulate in a stoppered, heated chamber.
Ten minutes before the onset of ischemia, the hearts were perfused with Krebs-Henseleit solution containing the appropriate concentration of drug or the vehicle used to dissolve the drug. Global ischemia was initiated by completely shutting off the perfusate flow, and this global ischemia was maintained for 25 min. Reperfusion with Krebs-Henseleit solution (without drug) was then initiated, and the hearts were allowed to recover for 30 min. Reperfusion cardiac function and coronary flow were then measured. At this time the reperfusion effluent was sampled for cumulative LDH release as previously described [21] . LDH was determined using a kit supplied by Medical Analysis Systems Inc. (Camarillo, CA) based on the technique of Wroblewski and LaDue [22] . LDH release was expressed as U/g preischemic heart weight for the 30-min collection period. Heart weight is calculated from a body weight/heart weight nomograph. LDH release was used as an indicator of cellular viability or membrane integrity [23] . As an additional index of cardioprotection, the time to the onset of contracture was calculated during global ischemia as the time necessary for the first 5 mmHg increase in EDP from baseline. Time to contracture was expressed as the percent change from vehicle-treated group values and potency was expressed as an EC,, which was the concentration necessary to increase time to contracture to 50% of the maximal effect for bromoenol lactone.
2.2.2. Experimental protocol for the evaluation of the cardioprotective effects of the bromoenol lactone Isolated rat hearts were prepared as described above. In one series of experiments, rat hearts were pretreated with vehicle (n = 81, 1, 2, 3, and 6 PM bromoenol lactone (n = 5 per concentration), 100 PM sodium 5hydroxyde-canoate (5HD, n = 51, 1 PM glyburide (n = 5), 100 PM 5-HD + 6 /IM bromoenol lactone (n = 51, or 1 PM glyburide + 6 PM bromoenol lactone (n = 5). One additional group was done in which a 0.3 PM concentration of the bromoenol lactone was administered and only time to contracture was determined (n = 5). This was done to complete a time to contracture-concentration response curve for this compound. The concentrations of glyburide and 5-HD used have been previously shown to inhibit the cardioprotective effects of K,,, openers during ischemia [24, 25] .
2.3. Calcium-independent PLA, assay 2.3.1. Tissue fractionation Isolated rat hearts were prepared as described above and the hearts were perfused with Krebs-Henseleit solution for 15 min. The hearts were then immediately plunged into ice-cold homogenization buffer containing 250 mM sucrose, 10 mM imidazole, 5 mM potassium phosphate buffer, 10 mM KCl, 1 mM dithiothreitol, 50 mM phenylmethylsulphonyl fluoride, 1 mg/ml aprotinin, pH 7.4. Tissue fractions were prepared according to previously reported protocols with slight modifications [lo] . Hearts from 4-6 rats were pooled and homogenized (25% w/v). The homogenate was centrifuged at 10000 X g (4"C, 20 min), and the supematant was removed and spun at 100000 X g (4"C, 60 min). The resultant supematant (cytosolic fraction) and pellet (membrane fraction) were frozen in aliquots at -80°C (PLA, activity is stable for more than 6 months at -80°C). Protein concentrations were determined using the method of Bradford [26] .
Assay
Membrane-associated PLA, activity was assayed using a modified procedure from Hazen et al. [27] . Specifically, PLA, activity was assayed in a mixture containing 100 pg of membrane fraction in 100 mM Tris (pH 7.01, 4 mM EGTA, 4 mM EDTA, 1 mM adenosine S-iminotriphosphate and 20 PM 3H-plasmalogen in a final assay volume of 257 ~1. The substrate was prepared by diluting 3H-plasmalogen with unlabeled plasmalogen to a final specific acitivity of 0.16 pCi/pmol and the resultant mixture was sonicated to form vesicles. Either vehicle (0.8% DMSO) or inhibitor (lo-6000 nM) were added to the enzyme mixture 5 min prior to initiation of the reaction by substrate addition at 25°C.
Substrate was added to the enzyme mixture following a 60-min incubation at 37"C, 100 ~1 butanol was added.
Following vortex mixing and centrifugation, free ['HIarachidonic acid was separated from the plasmalogen substrate by thin-layer chromatography [28] . An arachidonic acid standard was localized and the corresponding [3H]-arachidonic acid band was scraped and counted. In a representative assay the background comprised approximately 30% of the total counts detected in the presence of enzyme (only 0.2% of the total counts added to each assay). Product formation was linear for greater than 60 min at 37°C (between 10 pg and 200 pg of protein) and no substrate was hydrolyzed in the presence of heat-inactivated membranes.
Statistics
All data were analyzed using ANOVA. A Newman-Keuls post-hoc test was employed. All values are expressed as mean f s.e.m. Each PLA, assay is the representative of three separate experiments using different membrane preparations. The IC,, for inhibition of the calcium-independent PLA, was determined from a log fit to the data when expressed as a percent of vehicle group PLA, activity.
Results
Effects of bromoenol lactone in ischemic rat hearts
Cardiac function and coronary flow data for bromoenol lactone are shown in Table 1 . At 6 PM, bromoenol lactone slightly reduced pre-ischemic LVDP, although this was not observed at lower concentrations. Bromoenol lactone significantly increased pre-ischemic coronary flow at 6 PM. During reperfusion, no significant differences were observed in coronary flow in bromoenol lactone versus vehicle-treated hearts, although post-ischemic bradycardia was attenuated by bromoenol lactone. Reperfusion LVDP was significantly increased after pre-treatment with 2, 3 and 6 PM bromoenol lactone. During ischemia, time to the onset of contracture in hearts treated with 2-6 PM bromoenol lactone was significantly increased from vehicle, indicating cardioprotection (Fig. 2) . The EC,, for increasing time to contracture was 1.2 PM with the protective effect appearing to peak at 3-6 PM. LDH release was significantly reduced relative to vehicle values after pre-treatment with either 2, 3 or 6 PM bromoenol lactone (Fig. 3) . A reduction in reperfusion EDP was observed but significance was only reached with 6 PM bromoenol lactone (Fig. 3) .
3.2. EfSect of bromenol lactone on calcium-independent PLA, activity
In the presence of bromoenol lactone, inhibition of myocardial calcium-independent PLA 2 activity was assessed over a range of concentrations. In control experiments, DMSO added up to 0.8% had no effect on enzyme activity (data not shown). At concentrations up to 1 PM, the bromoenol lactone had minimal PLA, inhibitory activity (data not shown for lo-100 nM). The bromoenol lactone inhibited 100% of the calcium-independent PLA, in the assays at 6 PM and an IC,, of 0.87 PM was calculated from these experiments (0.3-6.0 PM Fig. 4 Fig. 3 . Effect of vehicle and the bromoenol lactone (I, 2, 3 and 6 PM) on reperfusion EDP (end diastolic pressure) and reperfusion LDH release in isolated perfused rat hearts. The hearts were subjected to 25 mitt global ischemia and 30 min reperfusion. * Significantly reduced from vehicle, P < 0.05.
Effect of KATP blockers on the cardioprotective efsects of calcium-independent PL.A, inhibitors
The cardiac function and coronary flow data for the combination of K,,, blockers with bromoenol lactone are shown in Table 2 . In hearts treated with the KATP blocker glyburide alone, there were no significant differences from vehicle in any of the non-ischemic, ischemic or reperfusion parameters measured, although glyburide did significantly reduce coronary flow and function compared to its paired pre-drug values. The significant increase in pre-ischemic coronary flow seen after treatment with 6 PM bromoenol lactone was abolished in the presence of glyburide. Cotreatment with bromoenol lactone and glyburide resulted in a significant decrease in pre-ischemic LVDP compared to time-matched vehicle-treated hearts. During reperfusion, bromoenol lactone significantly enhanced cardiac function (although function did not return to pre-ischemic values), an effect which was abolished by glyburide. During is-IC50 = 0.87 !dd $4 BROWEKL IACTGNE Fig. 4 . The effect of increasing concentrations of bromoenol lactone (data shown for 0.3-6 PM) on calcium-independent PLA, activity in membrane fractions prepared from isolated rat hearts. Enzyme activity is expressed as a percent of vehicle group activity (100%). An IC,, of 0.87 PM for inhibition of PLA, was calculated for the bromoenol lactone used in this study. Data ate from three experiments where each assay point was tested in triplicate.
chemia, the significant increase in time to contracture observed with bromoenol lactone was abolished by glyburide (Fig. 5) . The combination resulted in moderate pro-ischemic effects. During reperfusion, the significant Table 2 The effect of glyburide or 5-HD in the presence and absence of the bromoenol lactone PLA, inhibitor on contractile function and coronary flow in isolated perfused rat hearts reduction in EDP after treatment with 6 PM bromoenol lactone was abolished in the presence of 1 PM glyburide (Fig. 5) . The d t' re UC ton in LDH release by 6 PM bromoenol lactone was not completely abolished in the presence of 1 PM glyburide (Fig. 5) .
5-HD alone had no significant effect on any of the experimental parameters measured prior to, during or after global &hernia (Table 2) . 100 PM 5-HD did not affect the significant increase in coronary flow observed in the presence of bromoenol lactone. During global ischemia, the significant increase in time to the onset of contracture in the presence of bromoenol lactone was abolished in the presence of 5-HD and as observed for glyburide, some pro-ischemic effects of this combination were observed (Fig. 5) . Upon reperfusion, the bromoenol lactone-mediated increase in LVDP was abolished in the presence of 5443. Furthermore, the significant reductions in reperfu-sion EDP and LDH release seen after pre-treatment with bromoenol lactone were also abolished by 100 PM 5-HD (Fig. 5) . In hearts co-treated with bromoenol lactone and 5-HD, reperfusion coronary flow was significantly reduced compared to vehicle-treated hearts. However, there were no significant differences in reperfusion coronary flow in hearts treated with either 5-HD or bromoenol lactone alone.
Discussion
Since the initial identification of a calcium-independent PLA, in canine myocardium [7] , interest has been focused on understanding the physiological/pathophysiological role of this enzyme. To date this enzyme has been identified in several tissues; myocardium [s], smooth muscle [12] , pancreatic j3 cells [l 11 and renal epithelial cells [29] . Studies on the tissue distribution of this PLA, have shown the myocardium to have a relatively high activity [7, 8, 11, 12] . A unique characteristic of this particular PLA, appears to be its sensitivity to ATP [8, 9] . The presence of ATP stabilizes the activity of the enzyme and is suggestive of a link with cellular metabolism. A recent paper has demonstrated that an isoform of phosphofructokinase is specifically associated with the calcium-independent PLA 2 [ 131. A tetramer of the phosphofructokinase isoform makes up the regulatory unit of this PLA, presumably coordinating regulation of phospholipolysis and glycolysis.
An irreversible inhibitor of this calcium-independent PLA, was identified in rabbit myocardium [16] . This compound is a bromoenol lactone which was shown to be selective, showing no inhibitory activity for any calciumdependent PLA, [16l. In pancreatic p cells, the presence of this bromoenol lactone inhibited insulin and PGE, secretion [30] . Thus, the calcium-independent PLA, appears to be required for insulin release in pancreatic j3 cells. Although the heart has the greatest PLA, activity, little is known about its physiological role. During myocardial ischemia there is a significant time-dependent increase in this PLA, activity, which has substrate selectivity for plasmalogen phospholipids [ 14,151. Therefore, stimulation of this PLA, may be involved in ischemia-induced cellular damage. To determine a role for this PLA, , we determined the effect of inhibitors of this enzyme on severity of ischemia in isolated rat hearts.
Interestingly, we found that a bromoenol lactone inhibitor of myocardial PLA, activity protected ischemic myocardium. A steep, concentration-dependent increase in the time to onset of contracture was observed indicating ischemic protection. During reperfusion, a significant increase in contractile function and reduction in LDH release were observed, further demonstrating cardioprotection. The effective cardioprotective concentration of the bromoenol lactone was equivalent to that reported to inhibit insulin and PGE, release in pancreatic /3 cells [30] . A structurally distinct benzensulfonamide calcium-insensitive PLA, inhibitor has been shown to reduce infarct size in rats [17] . Our study further demonstrates that protection is mediated by a direct effect on the myocardium. However, the degree of cardioprotection with these PLA, inhibitors is moderate in our model when compared to hearts treated with K,, openers or other classical anti-ischemic agents, although we do not know if the bromoenol lactone represents an optimal pharmacologic inhibitor [311. At the highest concentrations of both PLA, inhibitors, a slight degree of cardiodepression and coronary vasodilation was observed in the non-ischemic myocardium.
Having determined that the bromoenol lactone PLA, inhibitor protected ischemic myocardium, we then determined whether the compound inhibited the same myocardial calcium-independent PLA, at cardioprotective concentrations. Utilizing similar methodology as Hazen et al. [ 161, we demonstrated that the bromoenol lactone inhibited the same myocardial calcium-independent PLA,. However, the absolute IC,, values were higher than those previously published. The reasons for this apparent discrepancy are not clear, but may be due to species differences as the previous values were reported for rabbit myocardium. Experiments in our laboratory with the bromoenol lactone demonstrated a lower IC,, value for rabbit tissue [28] which was comparable to the value reported by Hazen et al. [16] . For the bromoenol lactone, almost complete inhibition of this enzyme was observed at cardioprotective concentrations and there appeared to be a correlation between enzyme inhibition and cardioprotection. These data suggested that the bromoenol lactone was protecting the ischemic myocardium through inhibition of calcium-insensitive PLA 2. It also appears as if much of the enzyme must be inhibited to observe cardioprotection.
In a recent publication, Turk et al. [19] suggested that calcium-independent PLA, may modulate K,,, activity via arachidonic acid metabolism in insulin-secreting cells. Their hypothesis is that the PLA, is stimulated by ATP, causing hydrolysis of arachidonic acid and release of lipooxygenase products which may then inhibit K,, activity (K,,, blockade would enhance insulin release). We do not know whether a similar pathway exists in the heart, but it has been clearly shown that K,,, openers exert cardioprotective effects in ischemic myocardium. If this pathway works in the heart in a manner which is similar to insulin-secreting cells, then inhibition of the PLA, should attenuate a tonic inhibition of KATP which might be observed during ischemia and thereby increase channel open probability. Since KATP openers are protective, we reasoned that some or all of the cardioprotective effects of bromoenol lactone could be due to K,, activation.
Therefore we investigated the effects of two structurally different blockers of K,,, on the anti-ischemic activity of bromoenol lactone. Glyburide has been shown to be specific for the anti-ischemic actions of K,,, channel openers in isolated perfused rat hearts [31] . The anti-ischemic activity of KATP activators is completely abolished by 1 PM glyburide [3 1,321. N-ID has previously been shown to block the anti-ischemic activity of myocardial K,,, activators at 100 PM [25] . Interestingly the cardioprotective effects of the PLA, inhibitor were modulated by blockers of Km at concentrations which inhibited the cardioprotective effects of KATP openers. As observed with KATP openers, glyburide abolished the coronary vasodilator response observed with the bromoenol lactone, but 5-HD did not, as would be expected for the differing pharmacology of these compounds (the blocking activity of 5-HD is most pronounced in ischemic tissue [25] ). Taken in combination, the results from these studies suggest that bromoenol lactone is protecting ischemic hearts via K,, activation. It is also interesting that the combination of KATP blocker with PLA, inhibitor results in a pro-ischemic effect which was not observed for the agents alone. This is similar to results shown for K,, openers [24] and this can be explained by the fact that blockers and openers do not occupy the same receptor site, but their respective sites appear to be allosterically linked.
Presently, one working hypothesis for the mechanism of action of these compounds is based on the assumption that arachidonic acid release inhibits K,,.
Indeed, there are several reports which suggest arachidonic acid can directly modulate cardiac KATp [ 181. Therefore, in the presence of calcium-independent PLA, inhibitors, arachidonic acid release is inhibited and opening of K,,, is enhanced resulting in cardioprotection. This scheme is very similar to that proposed for insulinoma cells by Gross and co-workers. It should be pointed out that arachidonic acid has been shown by another group of investigators to activate KATP in insulinoma cells [33] . An interesting paper has recently been published showing that calcium-independent PLA, is an enzymic modulator of delayed rectifier potassium channel function [34] , although the relation of these findings to our data is presently unclear.
In conclusion the results in this paper suggest that activation of the calcium-independent PLA, is probably involved in the phospholipolysis and subsequent cellular damage observed during myocardial ischemia. Therefore inhibiton of the calcium-independent PLA, may be a potentially novel target for the treatment of myocardial ischemia. These results have identified a possible biochemical mechanism for the modulation of KATP in the myocardium. However, more experiments need to be performed to confirm whether the association is due to the enzyme itself or a product such as arachidonic acid, cycloxygenase or lipoxygenase. If arachidonic acid is involved, this would indicate a tonic inhibition of KATP such that during ischemia, these channels are not maximally opened. This is probably the case as K,, openers are protective in similar models of myocardial ischemia. It would be interesting if PLA, inhibition by the bromoenol lactone was causing an attenuation of a tonic inhibition of K ATP by arachidonic acid release during ischemia.
